Dr. Chari on Comparing Agents in Multiple Myeloma

Ajai Chari, MD
Published Online: Monday, Nov 13, 2017



Ajai Chari, MD, associate professor, Mount Sinai Hospital, discusses comparing agents in multiple myeloma.

The median overall survival of multiple myeloma has been on the rise, in part due to the plethora of novel agents that have emerged.

With 9 drugs approved in the last decade, choosing among the various regimens and combinations can be overwhelming, says Chari. Comparing these agents though is not so simple, as there are many variables to any given trial.
 


Ajai Chari, MD, associate professor, Mount Sinai Hospital, discusses comparing agents in multiple myeloma.

The median overall survival of multiple myeloma has been on the rise, in part due to the plethora of novel agents that have emerged.

With 9 drugs approved in the last decade, choosing among the various regimens and combinations can be overwhelming, says Chari. Comparing these agents though is not so simple, as there are many variables to any given trial.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Optimizing Treatment and Management of Soft Tissue Sarcoma in Community OncologyNov 30, 20171.5
Community Practice Connections™: 1st Annual European Congress on Immunotherapies in Cancer™Dec 13, 20171.5
Publication Bottom Border
Border Publication
x